Literature DB >> 29174488

Endpoints in sarcoidosis: More like IPF or asthma?

Marc A Judson1.   

Abstract

Entities:  

Keywords:  Asthma; Corticosteroids; Endpoints; IPF; Quality of life; Sarcoidosis

Mesh：

Year:  2017        PMID： 29174488     DOI： 10.1016/j.rmed.2017.11.010

Source DB:  PubMed          Journal:  Respir Med        ISSN： 0954-6111            Impact factor:   3.415


× No keyword cloud information.
  4 in total

1.  Predictors of cough-specific and generic quality of life in sarcoidosis patients.

Authors:  Branislav S Gvozdenovic; Violeta V Mihailovic-Vucinic; Mira H Vukovic; Mihailo I Stjepanovic; Ivana Buha; Strahinja V Mihailovic; Nikola B Maric
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

2.  Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes.

Authors:  Nynke A Kampstra; Paul B van der Nat; Lea M Dijksman; Frouke T van Beek; Daniel A Culver; Robert P Baughman; Elisabetta A Renzoni; Wim Wuyts; Vasilis Kouranos; Pieter Zanen; Marlies S Wijsenbeek; Marinus J C Eijkemans; Douwe H Biesma; Philip J van der Wees; Jan C Grutters
Journal:  ERJ Open Res       Date:  2019-10-30

3.  Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial.

Authors:  Robert P Baughman; Marc A Judson; Daniel A Culver; Surinder S Birring; Joseph Parambil; Joyce Zeigler; Elyse E Lower
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-09-30       Impact factor: 0.670

4.  The ability to predict the clinical course of pulmonary sarcoidosis from data that is right in front of us.

Authors:  Marc A Judson
Journal:  J Bras Pneumol       Date:  2022-02-02       Impact factor: 2.624
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.